Treatment of Canadian Postmenopausal Women With ER+ Advanced Breast Cancer in the Real-World Setting With Hormone Therapy ± Targeted Therapy
Condition: HR+ HER2- Postmenopausal Advanced Breast CancerInterventions: Drug: Endocrine therapy may include one of the following therapies: letrozole, anastrozole, exemestane, tamoxifen or fulvestrant; Drug: Endocrine therapy in combination with targeted therapy may include: everolimus plus exemestane or CDK4/6 inhibitor plus endocrine therapySponsor: Novartis PharmaceuticalsRecruiting - verified April 2016
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Arimidex | Breast Cancer | Cancer | Cancer & Oncology | Endocrine Therapy | HER2 | Hormonal Therapy | Hormones | Research | Tamoxifen | Women